The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Safety and tolerability of omalizumab
Abstract
Summary: Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti‐IgE antibody with proven efficacy in patients with moderate‐to‐severe and severe persistent allergic (IgE‐mediated) asthma. Objective To review clinical study data to assess the safety profile of omalizumab. Methods We analysed the safety of omalizumab using data from completed clinical studies (up to 1 year) involving more than 7500 patients with asthma, rhinitis or related conditions and up to 4 years in one study of patients with severe allergic asthma, as well as post‐marketing safety data. Analysis focuses on the risk of immune‐system effects, hypersensitivity reactions, malignant neoplasia, parasitic infections and thrombocytopenia. Results Omalizumab exhibited a good safety and tolerability profile that was maintained up to 4 years in one study. The incidence of anaphylaxis was 0.14% in omalizumab‐treated patients and 0.07% in control patients. No omalizumab‐treated patient developed measurable anti‐omalizumab antibodies. Post‐marketing, based on estimated exposure of 57 300 patients (June 2003–December 2006), the frequency of anaphylaxis attributed to omalizumab use was estimated to be at least 0.2% of patients. Current clinical trial data do not support an increased risk of malignant neoplasia or thrombocytopenia with omalizumab. Conclusion Data indicate that the proven efficacy of add‐on omalizumab in patients with moderate‐to‐severe or severe allergic asthma is accompanied by a favourable safety and tolerability profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,774
Statistical Methods for Rates and Proportions.
Everitt, B. S., & Fleiss, J. L. (1981) · Biometrics · doi:10.2307/2530193 · Cited by 8,990
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404073301402 · Cited by 2,589
Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson, N. F., Bock, S. A., Branum, A., Brown, S. G. A., Camargo, C. A., Cydulka, R., Galli, S. J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.1303 · Cited by 2,313
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Self-citationHumbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00772.x · Cited by 1,123
Middleton’s Allergy: Principles and Practice
Dorward, D. A., Lucas, C. G., Allen, K. C., & Rossi, A. G. (2013) · Cited by 833
Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
Self-citationMiddleton's Allergy: Principles and Practice
Adkinson, N. F., & Middleton, E. (2013) · Cited by 654
Djukanović, R., Wilson, S. J., Kraft, M., Jarjour, N. N., Steel, M., Chung, K. F., Bao, W., Fowler-Taylor, A., Matthews, J., Busse, W. W., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200312-1651oc · Cited by 646
Self-citationTreatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Milgrom, H., Berger, W., Nayak, A., Gupta, N., Pollard, S., McAlary, M., Taylor, A. F., & Rohane, P. (2001) · Pediatrics · doi:10.1542/peds.108.2.e36 · Cited by 525
Holgate, S. T., Chuchalin, A. G., Hébert, J., Lötvall, J., Persson, G. B., Chung, K. F., Bousquet, J., Kerstjens, H. A., Fox, H., Thirlwell, J., et al. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.1916.x · Cited by 522
Self-citationHumanization of an antibody directed against IgE.
Presta, L. G., Lahr, S. J., Shields, R. L., Porter, J. P., Gorman, C. M., Fendly, B. M., & Jardieu, P. M. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2623 · Cited by 474
Vignola, A. M., Humbert, M., Bousquet, J., Boulet, L., Hedgecock, S., Blogg, M., Fox, H., & Surrey, K. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00550.x · Cited by 405
Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., Fox, H., Hedgecock, S., Blogg, M., & Cioppa, G. D. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00770.x · Cited by 401
Self-citationCasale, T. B. (2001) · JAMA · doi:10.1001/jama.286.23.2956 · Cited by 377
Self-citationKuehr, J., Brauburger, J., Zielen, S., Schauer, U., Kamin, W., Von Berg, A., Leupold, W., Bergmann, K.-C., Rolinck-Werninghaus, C., Gräve, M., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121949 · Cited by 342
Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen–induced seasonal allergic rhinitis
Ädelroth, E., Rak, S., Haahtela, T., Aasand, G., Rosenhall, L., Zetterstrom, O., Byrne, A., Champain, K., Thirlwell, J., Cioppa, G. D., et al. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.108310 · Cited by 317
Cox, L., Platts-Mills, T. A. E., Finegold, I., Schwartz, L. B., Simons, F. E. R., & Wallace, D. V. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.09.032 · Cited by 295
Anaphylaxis: a review of 601 cases
Webb, L. M., & Lieberman, P. (2006) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)61367-1 · Cited by 286
Ayres, J. G., Higgins, B., Chilvers, E. R., Ayre, G., Blogg, M., & Fox, H. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00533.x · Cited by 279
Production and Activities of IgE in Helminth Infection
Jarrett, E. E. E., & Miller, H. R. P. (2015) · Chemical Immunology and Allergy · doi:10.1159/000406534 · Cited by 263
Chervinsky, P., Casale, T., Townley, R., Tripathy, I., Hedgecock, S., Fowler-Taylor, A., Shen, H., & Fox, H. (2003) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62171-0 · Cited by 215
Self-citationOmalizumab is effective in the long-term control of severe allergic asthma
Lanier, B. Q., Corren, J., Lumry, W., Liu, J., Fowler-Taylor, A., & Gupta, N. (2003) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62170-9 · Cited by 183
Self-citationOmalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Buhl, R., Solèr, M., Matz, J., Townley, R., O'Brien, J., Noga, O., Champain, K., Fox, H., Thirlwell, J., & Della Cioppa, G. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00278102 · Cited by 179
Self-citationOmalizumab improves asthma-related quality of life in patients with severe allergic asthma
Finn, A., Gross, G., van Bavel, J., Lee, T., Windom, H., Everhard, F., Fowler-Taylor, A., Liu, J., & Gupta, N. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.54 · Cited by 173
Limb, S. L., Starke, P. R., Lee, C. E., & Chowdhury, B. A. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.09.022 · Cited by 170
Cancer Incidence among 78 000 Asthmatic Patients
VESTERINEN, E., PUKKALA, E., TIMONEN, T., & AROMAA, A. (1993) · International Journal of Epidemiology · doi:10.1093/ije/22.6.976 · Cited by 162
Buhl, R., Hanf, G., Solèr, M., Bensch, G., Wolfe, J., Everhard, F., Champain, K., Fox, H., & Thirlwell, J. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00016502 · Cited by 160
Self-citationCruz, A. A., Lima, F., Sarinho, E., Ayre, G., Martin, C., Fox, H., & Cooper, P. J. (2007) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2007.02650.x · Cited by 111
Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment
Ruppert, A.-M., Avérous, G., Stanciu, D., Deroide, N., Riehm, S., Poindron, V., Pauli, G., Debry, C., & Frederic de, B. L. A. Y. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.10.040 · Cited by 64
Monoclonal antibody therapy in rheumatoid arthritis
Choy, E., Kingsley, G. H., & Panayi, G. S. (1998) · Lara D. Veeken · doi:10.1093/rheumatology/37.5.484 · Cited by 45
Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis
Casale, T. B., Condemi, J. J., LaForce, C., Nayak, A. S., Rowe, M. S., Watrous, M. L., McAlary, M., Gupta, N., Fick, R. B., & Cioppa, G. D. (2017) · Cited by 6
Self-citation
Cited by
Type 2 inflammation in asthma — present in most, absent in many
Fahy, J. V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3786 · Cited by 1,654
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Maurer, M., Rosén, K., Hsieh, H.-J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215372 · Cited by 1,105
Self-citationExploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 884
Metadata
- Authors
- Corren, J., Casale, T. B., Lanier, B., Buhl, R., Holgate, S., & Jimenez, P.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2009-05-11
- Volume
- 39
- Issue
- 6
- Pages
- 788-797
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W2137404654
- Cited by
- 252
- References
- 34
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.